NEW YORK, Feb. 27, 2017 /PRNewswire/ -- Levi & Korsinsky announces it has commenced an investigation of Argos Therapeutics, Inc. (ARGS). On February 22, 2017, an independent data monitoring committee recommended that Argos discontinue its Phase 3 ADAPT clinical trial of rocapuldencel-T for the treatment of metastic kidney cancer. Following this news, shares of Argos were down more than 66% on intraday trading on February 22, 2017. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-levi--korsinsky-llp-announces-an-investigation-involving-the-board-of-argos-therapeutics-inc----args-300414385.html